NUVALENT INC's ticker is and the CUSIP is 670703107. A total of 56 filers reported holding NUVALENT INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $113,244,842 | +22.4% | 2,463,451 | +12.2% | 3.78% | +41.0% |
Q2 2023 | $92,555,602 | +54.2% | 2,194,821 | -4.6% | 2.68% | +51.2% |
Q1 2023 | $60,008,252 | -10.6% | 2,300,048 | +2.0% | 1.77% | -6.0% |
Q4 2022 | $67,154,108 | +108.7% | 2,255,007 | +36.3% | 1.89% | +101.9% |
Q3 2022 | $32,173,000 | +43.4% | 1,655,007 | 0.0% | 0.93% | +32.9% |
Q2 2022 | $22,442,000 | -7.8% | 1,655,007 | -5.5% | 0.70% | +44.4% |
Q1 2022 | $24,330,000 | -14.8% | 1,751,601 | +16.8% | 0.49% | +121.4% |
Q4 2021 | $28,560,000 | +68.9% | 1,500,000 | +100.0% | 0.22% | -10.6% |
Q3 2021 | $16,913,000 | – | 750,000 | – | 0.25% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 19,991,024 | $918,987,373 | 20.25% |
Bain Capital Life Sciences Investors, LLC | 3,577,267 | $164,446,964 | 18.39% |
Fairmount Funds Management LLC | 2,451,819 | $112,710,119 | 13.56% |
Paradigm Biocapital Advisors LP | 1,638,147 | $75,305,618 | 5.11% |
COMMODORE CAPITAL LP | 828,778 | $38,098,925 | 4.45% |
Perceptive Advisors | 2,463,451 | $113,244,842 | 3.78% |
Boxer Capital, LLC | 1,210,192 | $55,632,526 | 2.96% |
Tri Locum Partners LP | 113,528 | $5,218,882 | 1.67% |
Ikarian Capital, LLC | 278,034 | $12,781,224 | 1.54% |
Ikarian Capital, LLC | 2,395 | $11,009,815 | 1.32% |